SAFETY AND PHARMACODYNAMICS OF MULTIPLE DOSES OF FTY720.
Barry D. Kahan(University of Houston), Tomasz Sablinski(Icahn School of Medicine at Mount Sinai), Jennifer Dehlinger(Novartis (Switzerland)), Lawrence Chodoff(Octane Wireless (United States)), Alan B. Leichtman(University of Michigan), Robert Schmouder(Novartis (United States)), Milbhor D’Silva, Thomas Maher(Novartis (Switzerland)), Ronald M. Ferguson(Instituto do Sono), Janet L. Karlix(UF Health Shands Hospital)
Cited by 6
Related Papers
Kidney Transplantation as Primary Therapy for End-Stage Renal Disease
|Clinical Journal of the American Society of Nephrology|2008|606
First Human Trial of FTY720, a Novel Immunomodulator, in Stable Renal Transplant Patients
|Journal of the American Society of Nephrology|2002|274
A randomized controlled trial with an anti‐CCL2 (anti–monocyte chemotactic protein 1) monoclonal antibody in patients with rheumatoid arthritis
|Arthritis & Rheumatism|2006|255
REMOVAL OF ANTI-PORCINE NATURAL ANTIBODIES FROM HUMAN AND NONHUMAN PRIMATE PLASMA IN VITRO AND IN VIVO BY A Gal??1-3Gal??1-4??Glc-X IMMUNOAFFINITY COLUMN
|Transplantation|1998|196
Specific tolerance across a discordant xenogeneic transplantation barrier.
|Proceedings of the National Academy of Sciences|1994|116